$6.78
1.47%
Downside
Day's Volatility :11.17%
Upside
9.84%
48.97%
Downside
52 Weeks Volatility :69.65%
Upside
40.53%
Period | Terns Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 6.7% | -2.6% | 0.0% |
6 Months | 21.73% | 2.6% | 0.0% |
1 Year | 112.76% | 15.9% | 0.0% |
3 Years | -15.55% | 10.0% | -26.7% |
Market Capitalization | 629.9M |
Book Value | $3.11 |
Earnings Per Share (EPS) | -1.32 |
Wall Street Target Price | 18.64 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -25.99% |
Return On Equity TTM | -38.92% |
Revenue TTM | 1000.0K |
Revenue Per Share TTM | 0.04 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 1000.0K |
EBITDA | -107.9M |
Diluted Eps TTM | -1.32 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.27 |
EPS Estimate Next Year | -1.39 |
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Next Quarter | -0.35 |
What analysts predicted
Upside of 174.93%
Sell
Neutral
Buy
Terns Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Terns Pharmaceuticals Inc | -5.91% | 21.73% | 112.76% | -15.55% | -61.01% |
Regeneron Pharmaceuticals, Inc. | -19.05% | -15.96% | 3.05% | 26.75% | 135.72% |
Biontech Se | -11.5% | 14.67% | 8.57% | -57.55% | 473.15% |
Alnylam Pharmaceuticals, Inc. | -5.07% | 79.43% | 62.99% | 55.18% | 196.92% |
Vertex Pharmaceuticals Incorporated | 1.07% | 13.97% | 29.31% | 162.23% | 136.6% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Terns Pharmaceuticals Inc | NA | NA | NA | -1.27 | -0.39 | -0.26 | NA | 3.11 |
Regeneron Pharmaceuticals, Inc. | 20.49 | 20.49 | 1.23 | 44.94 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.18 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.88 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.35 | 0.42 | -0.03 | 0.12 | NA | 60.65 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Terns Pharmaceuticals Inc | Buy | $629.9M | -61.01% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $91.0B | 135.72% | 20.49 | 33.61% |
Biontech Se | Buy | $26.1B | 473.15% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.1B | 196.92% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $133.1B | 136.6% | 32.84 | -4.51% |
Insights on Terns Pharmaceuticals Inc
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 57.4% return, outperforming this stock by 77.1%
Orbimed Advisors, LLC
Vivo Capital, LLC
Deep Track Capital, LP
Soleus Capital Management, L.P.
BlackRock Inc
VR Adviser, LLC
terns pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver diseases and cancers. the company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in china to advance its growing pipeline of drugs that are optimized against clinically-validated targets. based in san mateo, california and shanghai, terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in china and globally.
Organization | Terns Pharmaceuticals Inc |
Employees | 66 |
CEO | Dr. Mark Joseph Vignola Ph.D. |
Industry | Services |